In the two negative short-term efficacy trials that did not reach statistical significance (TRANSFORM-1 and -3), the differences in MADRS reductions between esketamine and placebo were –3.2 (P = 0.088) and –3.6 (P = 0.059) after 4 weeks of treatment. The 4.0-point additional reduction in MADRS score with esketamine over placebo in the single positive efficacy trial corresponds to less than "minimal improvement" and has been criticized as being below the threshold for clinically meaningful change. A difference of at least 6.5 points was originally suggested by the trial investigators to be a reasonable threshold for clinical significance. In other literature, MADRS reductions have been interpreted as "very much improved" corresponding to 27–28 points, "much improved" to 16–17 points, and "minimally improved" to 7–9 points. It has additionally been argued that the small advantage in scores with esketamine may have been related to an enhanced placebo response in the esketamine group due to functional unblinding caused by the psychoactive effects of esketamine. In other words, it is argued that the study was not truly a double-blind controlled trial. Dissociation was experienced as a side effect by a majority of participants who received esketamine (61–75% with esketamine and 5–12% with placebo; ~7-fold difference) and "severe" dissociation was experienced by 25%. Deblinding and expectancy confounds are problems with studies of hallucinogens for psychiatric indications in general.
There are also sixty-four (or 64 = 43) four-dimensional Bravais lattices, and sixty-four uniform polychora in the fourth dimension based on the same 
  
    
      
        
          
            A
          
          
            4
          
        
      
    
    {\displaystyle \mathrm {A} _{4}}
  , 
  
    
      
        
          
            B
          
          
            4
          
        
      
    
    {\displaystyle \mathrm {B} _{4}}
  , 
  
    
      
        
          
            F
          
          
            4
          
        
      
    
    {\displaystyle \mathrm {F} _{4}}
   and 
  
    
      
        
          
            H
          
          
            4
          
        
      
    
    {\displaystyle \mathrm {H} _{4}}
   Coxeter groups, and extending to prismatic groups of uniform polyhedra, including one special non-Wythoffian form, the grand antiprism.